The risk for antidrug antibodies during antitumor necrosis factor therapy in patients with inflammatory bowel disease may be reduced with the appropriate choice of antibiotics, according to a new study.
Medscape Medical News
The risk for antidrug antibodies during antitumor necrosis factor therapy in patients with inflammatory bowel disease may be reduced with the appropriate choice of antibiotics, according to a new study.
Medscape Medical News
